The Global Pyrimethamine Market, by Indication (Toxoplasmosis, Malaria, and Others), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) is estimated to be valued at US$ 1,106.8 Million in 2022 and projected to exhibit a CAGR of 5.2% during the forecast period (2022-2030).
Key market players are focusing on the introduction of generic versions of pyrimethamine, which is projected to provide a profitable opportunity for industry participants to introduce their novel products. For instance, in March 2020, Dr. Reddy's Laboratories Ltd., a leading multinational pharmaceutical company, announced the launch of the U.S. Food and Drug Administration (USFDA) approved pyrimethamine 25 mg tablet, which is the first-wave generic version and a therapeutic equivalent of Daraprim (pyrimethamine) tablets.
Global Pyrimethamine Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic has affected various industries globally. Key players operating in the global pyrimethamine market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of February 7, 2022, are approximately 394,381,395 confirmed cases with 5,735,179 deaths.
The COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are also facing problems with regard to the transportation of several drugs from one place to another.
Browse 35 Market Data Tables and 29 Figures spread through 178 Pages and in-depth TOC on “Global Pyrimethamine Market” - Forecast to 2030, Global Pyrimethamine Market, by Indication (Toxoplasmosis, Malaria, and Others), by Route of Administration (Parenteral and Oral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America).
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pyrimethamine-market-4948
The rising prevalence of cancer and chemotherapy procedures may lead to toxoplasmosis infection (as they lower the number of white blood cells), which in turn will increase the demand for pyrimethamine for the treatment. This is expected to drive the global pyrimethamine market growth over the forecast period. For instance, in 2018, about 17 million people were diagnosed with cancer worldwide, according to Cancer Research UK's factsheet.
Key Takeaways of the Global Pyrimethamine Market:
- The global pyrimethamine market is expected to exhibit a CAGR of 5.2% during the forecast period, owing to an increase in the number of cases of toxoplasmosis and chronic diseases such as cancer. Patients with solid organ tumors treated with chemotherapy had the highest incidence rate of toxoplasmosis (28%), according to a study published in the National Center for Biotechnology Information (NCBI) in 2018. According to the same source, males (26%) had higher infection rates than females (10%) in the Egyptian cancer population.
- Among the route of administration, the oral route of administration is expected to dominate the global pyrimethamine market in the forecast period, since the majority of the generics (e.g.: Daraprim (pyrimethamine) tablets) that are launched are in the form of tablets.
- Major players operating in the global pyrimethamine market include Vyera Pharmaceuticals, LLC, Cerovene Healthcare PVT. LTD, GlaxoSmithKline plc, Impax Laboratories, Inc., NCBO BioPortal, Pfizer, Inc., PRN Pharmacal, SUDA Pharmaceuticals, Taj Accura Pharmaceuticals, TargetMo Chemicals Inc., Evaluate Ltd., and Abcam
